Larvol Delta - Apnimed-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-with-AD109-Lead-Candidate-for-Treatment-of-Obstructive-Sleep-Apnea

atomoxetine/R-oxybutynin (AD109) - Apnimed

https://www.businesswire.com/news/home/20201124005389/en/Apnimed-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-with-AD109-Lead-Candidate-for-Treatment-of-Obstructive-Sleep-Apnea

Nov 24, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next